the annual 2015 financial results of acelrx pharmaceuticals ( acx ) are reviewed in order to provide an overview of the process and timing of anticipated future development of acelrx. we will make forward - looking statements relating to the process and timing of anticipated future development of acelrx's product candidates including the process and timing of anticipated future development of arx-04 andzalviso. anticipated results and completion of the sap302 and sap303 studies for arx-04 and the initiation and completion along with anticipated results of ip312 for zalviso, launched timing and commercial availability for zalviso european and anticipated resubmission of the dna to the FDA including the scope and timing of resubmission and the cash guidance for the year.